Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics in pediatrics. Implications for practice

J S Leeder1, G L Kearns

  • 1Department of Pediatrics, University of Missouri-Kansas City, USA.

Pediatric Clinics of North America
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.

Pediatric obesity·2018
Same author

Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders.

Alimentary pharmacology & therapeutics·2018
Same author

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Clinical pharmacology and therapeutics·2017
Same author

Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics.

Clinical pharmacology and therapeutics·2016
Same author

Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.

Clinical and translational science·2016
Same author

Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.

Clinical pharmacology and therapeutics·2015
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Prescribing medications for children is complex, as age alone is insufficient for rational drug selection. Understanding drug metabolism and its influencing factors is crucial for effective pediatric pharmacotherapy and minimizing adverse events.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Metabolism

Background:

  • Pediatric pharmacotherapy is challenging due to difficulties in rational drug prescription based solely on age.
  • Drug biotransformation can be significantly affected by disease, environmental factors, and co-administered drugs.

Purpose of the Study:

  • To emphasize the necessity of characterizing drug biotransformation pathways in pediatric drug development.
  • To identify patient population outliers to optimize dosage ranges for efficacy studies.
  • To integrate acquired knowledge into drug design for improved efficacy-toxicity ratios.

Main Methods:

  • Characterization of drug biotransformation pathways during drug development.
  • Investigating the effects of known modulators on drug biotransformation at different developmental stages.

Related Experiment Videos

  • Developing noninvasive phenotyping procedures for all pediatric age groups.

    • Main Results:

    • Altered drug biotransformation can lead to therapeutic failure, such as graft rejection or antineoplastic agent toxicity.
    • Identifying population extremes in drug metabolism is essential for establishing appropriate pediatric dosage ranges.
    • Characterizing pediatric drug metabolism aids in maximizing the efficacy-toxicity ratio.

    Conclusions:

    • Comprehensive understanding of pediatric drug metabolism is vital for optimizing treatment outcomes.
    • Development of robust phenotyping methods is a key challenge for advancing pediatric pharmacotherapy.
    • Improved pediatric pharmacotherapy relies on coordinated clinical and basic research into drug biotransformation.